Virtu Financial LLC Has $1.14 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Key Points

• Virtu Financial LLC increased its holdings in IQVIA Holdings Inc. by 46.3%, owning a total of 6,480 shares valued at $1,142,000 after purchasing an additional 2,050 shares in the first quarter.
• IQVIA reported earnings of $2.81 per share for the last quarter, beating estimates by $0.04, and had a revenue of $4.02 billion, surpassing expectations of $3.96 billion.
• Analysts have varying views on IQVIA, with target prices ranging from $165.00 to $225.00, and a consensus rating of "Moderate Buy" based on multiple upgrades from recent research reports.

Virtu Financial LLC increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 46.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,480 shares of the medical research company's stock after acquiring an additional 2,050 shares during the period. Virtu Financial LLC's holdings in IQVIA were worth $1,142,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Continuum Advisory LLC boosted its stake in shares of IQVIA by 3.7% during the fourth quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock valued at $354,000 after acquiring an additional 64 shares during the last quarter. Ballentine Partners LLC lifted its position in IQVIA by 4.9% during the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock worth $260,000 after acquiring an additional 69 shares in the last quarter. ST Germain D J Co. Inc. lifted its stake in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares in the last quarter. Nemes Rush Group LLC lifted its position in shares of IQVIA by 15.0% during the first quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock worth $109,000 after purchasing an additional 81 shares during the last quarter. Finally, Atria Wealth Solutions Inc. grew its position in shares of IQVIA by 5.6% during the 1st quarter. Atria Wealth Solutions Inc. now owns 1,812 shares of the medical research company's stock valued at $319,000 after buying an additional 96 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Price Performance

Shares of IQV stock traded down $0.73 during mid-day trading on Thursday, reaching $189.50. The company's stock had a trading volume of 946,600 shares, compared to its average volume of 1,995,617. The company has a market cap of $32.21 billion, a P/E ratio of 27.42, a PEG ratio of 2.04 and a beta of 1.30. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88. The firm's 50-day moving average is $169.61 and its two-hundred day moving average is $168.92.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same quarter in the previous year, the firm earned $2.64 earnings per share. The business's revenue was up 5.3% on a year-over-year basis. On average, research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on IQV. Hsbc Global Res lowered IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Redburn Partners set a $188.00 target price on IQVIA in a research note on Friday, May 23rd. Mizuho increased their price target on IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Robert W. Baird increased their target price on shares of IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. Finally, Citigroup reiterated a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Seven investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $228.62.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.